| In Vitro Methods to Support Transporter Evaluation in Drug Discovery and Development KLR Brouwer, D Keppler, KA Hoffmaster, DAJ Bow, Y Cheng, Y Lai, ... Clinical Pharmacology & Therapeutics 94 (1), 95-112, 2013 | 270 | 2013 |
| Localization of P-gp (Abcb1) and Mrp2 (Abcc2) in freshly isolated rat hepatocytes DAJ Bow, JL Perry, DS Miller, JB Pritchard, KLR Brouwer Drug metabolism and disposition 36 (1), 198-202, 2008 | 135 | 2008 |
| Prediction of clinical drug–drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K) R Kikuchi, Y Lao, DAJ Bow, WJ Chiou, ME Andracki, RA Carr, ... Journal of pharmaceutical sciences 102 (12), 4426-4432, 2013 | 64 | 2013 |
| Mechanistic physiologically based pharmacokinetic modeling of the dissolution and food effect of a biopharmaceutics classification system IV compound—the venetoclax story AE Riedmaier, DJ Lindley, JA Hall, S Castleberry, RT Slade, P Stuart, ... Journal of pharmaceutical sciences 107 (1), 495-502, 2018 | 63 | 2018 |
| Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat. B Renjifo, J van Wyk, A Hamed Salem, D Bow, J Ng, M Norton AIDS reviews 17 (1), 2015 | 53 | 2015 |
| Molecular aspects of the transport and toxicity of ochratoxin A J Dai, G Park, JL Perry, YV Il'ichev, DAJ Bow, JB Pritchard, V Faucet, ... Accounts of chemical research 37 (11), 874-881, 2004 | 52 | 2004 |
| The impact of plasma protein binding on the renal transport of organic anions DAJ Bow, JL Perry, JD Simon, JB Pritchard Journal of Pharmacology and Experimental Therapeutics 316 (1), 349-355, 2006 | 49 | 2006 |
| Mechanisms and predictions of drug-drug interactions of the hepatitis C virus three direct-acting antiviral regimen: paritaprevir/ritonavir, ombitasvir, and dasabuvir M Shebley, J Liu, O Kavetskaia, J Sydor, SM de Morais, V Fischer, ... Drug Metabolism and Disposition 45 (7), 755-764, 2017 | 38 | 2017 |
| In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia WJ Chiou, SM de Morais, R Kikuchi, RL Voorman, X Li, DAJ Bow Xenobiotica 44 (3), 276-282, 2014 | 37 | 2014 |
| Physiologically based pharmacokinetic modeling suggests limited drug–drug interaction between clopidogrel and dasabuvir M Shebley, W Fu, P Badri, DAJ Bow, V Fischer Clinical Pharmacology & Therapeutics 102 (4), 679-687, 2017 | 31 | 2017 |
| A mechanistic non-clinical assessment of drug-drug interactions (metabolism and transporters) with the hepatitis C virus (HCV) regimen: ABT-450/r, ombitasvir and dasabuvir DAJ Bow, J Liu, O Kavetskaia, R Menon, SM de Morais, M Nijsen, J Sydor, ... Poster presented at, 2014 | 28 | 2014 |
| Coproporphyrin I can serve as an endogenous biomarker for OATP1B1 inhibition: assessment using a Glecaprevir/Pibrentasvir clinical study HV Kalluri, R Kikuchi, S Coppola, J Schmidt, MEF Mohamed, DAJ Bow, ... Clinical and Translational Science 14 (1), 373-381, 2021 | 17 | 2021 |
| International Transporter C (2013) In vitro methods to support transporter evaluation in drug discovery and development KL Brouwer, D Keppler, KA Hoffmaster, DA Bow, Y Cheng, Y Lai, JE Palm, ... Clin Pharmacol Ther 94 (1), 95-112, 0 | 17 | |
| Translation of in vitro transport inhibition studies to clinical drug-drug interactions for glecaprevir and pibrentasvir MP Kosloski, DAJ Bow, R Kikuchi, H Wang, EJ Kim, K Marsh, F Mensa, ... Journal of Pharmacology and Experimental Therapeutics 370 (2), 278-287, 2019 | 16 | 2019 |
| ABT-450/ritonavir+ ombitasvir+ dasabuvir: drug interactions mediated by transporters R Menon, P Badri, A Khatri, T Wang, AR Polepally, TJ Podsadecki 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis …, 2014 | 14 | 2014 |
| Validation of a total IC50 method which enables in vitro assessment of transporter inhibition under semi-physiological conditions R Kikuchi, VC Peterkin, WJ Chiou, SM de Morais, DAJ Bow Xenobiotica 47 (9), 825-832, 2017 | 13 | 2017 |
| Prodrug strategies to improve the solubility of the HCV NS5A inhibitor pibrentasvir (ABT-530) JT Randolph, EA Voight, SN Greszler, BE Uno, JN Newton, KM Gleason, ... Journal of Medicinal Chemistry 63 (19), 11034-11044, 2020 | 11 | 2020 |
| 2013 I BROUWER, D Keppler, KA Hoffmaster, DAJ Bow, Y Chen, ... vitro methods to support transporter evaluation in drug discovery and …, 2000 | 11 | 2000 |
| In vitro characterization of drug metabolizing enzymes and transporters to enable a mechanistic drug-drug interaction assessment for venetoclax R Kikuchi, M Shebley, DAJ Bow, RA Carr, M Nijsen, SM de Morais Drug Metabolism and Pharmacokinetics 32 (1), S51, 2017 | 7 | 2017 |
| Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors JT Randolph, T Li, AC Krueger, HR Heyman, HJ Chen, DAJ Bow, ... Bioorganic & Medicinal Chemistry Letters 30 (7), 126986, 2020 | 6 | 2020 |
